相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor
Anat Norden-Zfoni et al.
CLINICAL CANCER RESEARCH (2007)
Chemotherapy for metastatic breast cancer
Erica L. Mayer et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer
Laura Orlando et al.
ANTI-CANCER DRUGS (2006)
Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones
Yayun Liang et al.
ENDOCRINE-RELATED CANCER (2006)
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
Patrizia Mancuso et al.
BLOOD (2006)
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy
R Munoz et al.
CANCER RESEARCH (2006)
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts
JM du Manoir et al.
CLINICAL CANCER RESEARCH (2006)
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer:: antitumor activity and biological effects
M Colleoni et al.
ANNALS OF ONCOLOGY (2006)
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
BT Hennessy et al.
ANNALS OF ONCOLOGY (2005)
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer
L Rydén et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines
E Karl et al.
CANCER RESEARCH (2005)
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity
P Beaudry et al.
CLINICAL CANCER RESEARCH (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Capecitabine: Fixed daily dose and continuous (noncyclic) dosing schedule
J Lokich
CANCER INVESTIGATION (2004)
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors
T Vogt et al.
CANCER (2003)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
LM Glode et al.
CANCER (2003)
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study
K Spieth et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
M Colleoni et al.
ANNALS OF ONCOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Aquaporins and the respiratory system: advice for a lung investigator
LS King et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
